Gwenn Smith

Medicine & Life Sciences

1. Positron-Emission Tomography 100%
2. Alzheimer Disease 96%
3. Deep Brain Stimulation 71%
4. Cognitive Dysfunction 61%
5. Citalopram 56%
6. Serotonin 53%
7. Geriatrics 47%
8. Glucose 45%
9. Brain 40%
10. Antidepressive Agents 36%
11. altanserin 32%
12. Dopamine 31%
13. Raclopride 31%
14. Dementia 31%
15. Molecular Imaging 30%
16. Amyloid 28%
17. Corpus Striatum 27%
18. Sleep Deprivation 26%
19. Gyrus Cinguli 26%
20. Neuroimaging 25%
21. Serotonin Plasma Membrane Transport Proteins 21%
22. Cholinergic Agents 21%
23. Parkinson Disease 20%
24. Neurotransmitter Agents 20%
25. Receptor, Serotonin, 5-HT2A 20%
26. Parietal Lobe 19%
27. Paroxetine 19%
28. Temporal Lobe 19%
29. Research Subjects 19%
30. Therapeutics 18%
31. Brain Fornix 17%
32. 3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide 16%
33. Serotonin Uptake Inhibitors 16%
34. Gray Matter 15%
35. Cerebrovascular Circulation 15%
36. Dopamine Plasma Membrane Transport Proteins 14%
37. Psychiatry 13%
38. Memory 13%
39. Regional Blood Flow 13%
40. White Matter 13%
41. Single-Photon Emission-Computed Tomography 13%
42. Scopolamine 13%
43. Elderly 12%
44. Football 12%
45. Sleep 12%
46. Cerebellum 12%
47. Cognition 12%
48. Healthy Volunteers 12%
49. Frontal Lobe 11%